Finance

Lists
Outlook: 78.1% bullish·1.6% bearish
Go to analysis
ABBV:NYSE
AbbVie Common Stock
$276.47
+1.49%
(+4.05) 1D
$276.43
-0.01% (-0.040)
After hours
Closed: Oct 9, 4:01:20 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ABBV...
Open
$271.53
High
$277.60
Low
$270.38
Mkt. cap
488.55B
Avg. vol.
4.42M
Volume
4.30M
Dividend
2.50%
Quarterly dividend
$1.73
Ex-dividend date
Oct 15, 2026
P/E ratio
78.19
52-wk high
$277.60
52-wk low
$190.75
EPS
$3.54
Beta
0.23
Shares outstanding
1.77B
No. of employees
57K
Open
$271.53
High
$277.60
Low
$270.38
Mkt. cap
488.55B
Avg. vol.
4.42M
Volume
4.30M
Dividend
2.50%
Quarterly dividend
$1.73
Ex-dividend date
Oct 15, 2026
P/E ratio
78.19
52-wk high
$277.60
52-wk low
$190.75
EPS
$3.54
Beta
0.23
Shares outstanding
1.77B
No. of employees
57K
News stories
From web sources and news partners
Profile
AbbVie Inc., also known as AbbVie, is an American pharmaceutical company headquartered in North Chicago, Illinois. AbbVie produces drugs to treat a wide range of medical issues. The company is ranked sixth on the list of largest biomedical companies by revenue. It is ranked 77th on the Fortune 500 and 108th on the Forbes Global 2000. The name "AbbVie" is derived from a combination of "Abbott", the name of its former parent company, with "vie", intended as a reference to a Latin root meaning 'life'. Wikipedia
About AbbVie Common Stock
CEORobert A. Michael
Employees57K
FoundedApr 10, 2012
HeadquartersNorth Chicago, Illinois, United States
SectorBiotechnology
Websiteabbvie.com
Analyst ratings
Based on 24 analysts giving stock ratings to ABBV in the past 3 months
Strong buy
Buy
20
Hold
4
Sell
0
12-month forecast
Based on 24 Wall Street analysts offering 12 month price targets for ABBV in the last 3 months.
Highest
Current $276.47
$320.00 (+15.74%)
Average
$286.67 (+3.69%)
Lowest
$225.00 (-18.62%)
Analyst
Recommendation
Action
Price target
Projected
Date
Vamil Divan
Guggenheim
Buy
Reiterated
$288.00
+4.2%
10/08/2026
Michael Yee
UBS
Hold
Reiterated
$275.00
-0.5%
10/09/2026
Jason Gerberry
Bank of America Securities
Buy
Maintained
$305.00
+10.3%
10/09/2026
Chris Schott
J.P. Morgan
Buy
Reiterated
$300.00
+8.5%
10/08/2026
Carter Gould
Cantor Fitzgerald
Buy
Reiterated
$290.00
+4.9%
10/08/2026
David Amsellem
Piper Sandler
Buy
Reiterated
$303.00
+9.6%
10/08/2026
David Risinger
Leerink Partners
Buy
Reiterated
-
-
10/07/2026
Terence Flynn
Morgan Stanley
Buy
Reiterated
$310.00
+12.1%
10/07/2026
Louise Chen
Scotiabank
Buy
Reiterated
$320.00
+15.7%
10/06/2026
Gary Nachman
Canaccord Genuity
Buy
Reiterated
$290.00
+4.9%
09/28/2026
Evan Seigerman
BMO Capital
Buy
Reiterated
$300.00
+8.5%
09/29/2026
Geoff Meacham
Citi
Hold
Maintained
$260.00
-6%
09/29/2026
Tim Anderson
Bank of America Securities
Buy
Reiterated
$289.00
+4.5%
09/29/2026
Trung Huynh
RBC Capital
Buy
Maintained
$280.00
+1.3%
09/29/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
09/28/2026
Steve Scala
TD Cowen
Buy
Maintained
$280.00
+1.3%
09/28/2026
Luisa Hector
Berenberg Bank
Buy
Reiterated
$275.00
-0.5%
09/10/2026
Rajesh Kumar
HSBC
Buy
Maintained
$315.00
+13.9%
09/10/2026
William Katz
TD Cowen
Buy
Reiterated
$280.00
+1.3%
09/04/2026
Mohit Bansal
Wells Fargo
Buy
Reiterated
$300.00
+8.5%
08/17/2026
Alexandria Hammond
Wolfe Research
Buy
Upgraded
$300.00
+8.5%
08/13/2026
Emily Field
Barclays
Buy
Reiterated
$300.00
+8.5%
08/11/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Reiterated
$260.00
-6%
08/10/2026
Hans Engel
Erste Group
Buy
Upgraded
-
-
08/05/2026
Courtney Breen
Bernstein
Hold
Maintained
$225.00
-18.6%
07/22/2026
Asad Haider
Goldman Sachs
Hold
Maintained
$244.00
-11.7%
07/21/2026
Michael Harvey
RBC Capital
Buy
Reiterated
$280.00
+1.3%
07/10/2026
Tyler Van Buren
TD Cowen
Buy
Reiterated
$280.00
+1.3%
06/23/2026
Nicholas Lorusso
TD Cowen
Buy
Reiterated
$280.00
+1.3%
06/23/2026
Jasper Hellweg
Argus Research
Buy
Reiterated
$250.00
-9.6%
05/13/2026
Unknown Analyst
Canaccord Genuity
Buy
Initiated
$262.00
-5.2%
04/20/2026
Nico Chen
DBS
Hold
Maintained
$230.00
-16.8%
02/25/2026
Last report
Jul 31, 2026
Fiscal period
Q2 2026
$3.65 / $3.61
+1.15%beat
Revenue / Est. (USD)
16.99B / 16.76B
+1.36%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
15.78B
16.62B
15.00B
16.99B
Cost of goods sold
4.46B
4.55B
4.22B
4.29B
Cost of revenue
4.46B
4.55B
4.22B
4.29B
Research and development expenses
2.29B
2.58B
2.47B
2.34B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.43B
3.82B
3.49B
3.55B
Operating expense
5.72B
6.40B
5.96B
5.90B
Total operating expenses
10.18B
10.95B
10.18B
10.19B
Operating income
5.60B
5.67B
4.82B
6.80B
Other non operating income
199.00M
120.00M
-3.00M
-55.00M
EBT including unusual items
714.00M
2.67B
1.04B
4.28B
EBT excluding unusual items
5.11B
5.12B
4.19B
6.07B
Income tax expense
526.00M
853.00M
342.00M
662.00M
Effective tax rate
73.67%
31.97%
32.92%
15.47%
Other operating expenses
-
-
-
-
Net income
186.00M
1.82B
695.00M
3.61B
Net profit margin
1.18%
10.93%
4.63%
21.27%
Earnings per share
1.86
2.71
2.65
3.65
Interest and investment income
72.00M
59.00M
72.00M
67.00M
Interest expense
-739.00M
-714.00M
-717.00M
-746.00M
Net interest expenses
-667.00M
-655.00M
-645.00M
-679.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
7.66B
7.66B
6.76B
8.68B
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps